Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease

INTRODUCTION: Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US Food and Drug Administration to reduce a defining pathophysiological feature of the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Herring, William L., Gould, Ian Gopal, Fillit, Howard, Lindgren, Peter, Forrestal, Fiona, Thompson, Robin, Pemberton-Ross, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571451/
https://www.ncbi.nlm.nih.gov/pubmed/34426940
http://dx.doi.org/10.1007/s40120-021-00273-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571451/
https://www.ncbi.nlm.nih.gov/pubmed/34426940
http://dx.doi.org/10.1007/s40120-021-00273-0

Ejemplares similares